Dasatinib, a multi-target tyrosine kinase inhibitor, is primarily employed in chronic myeloid leukemia and other malignancies driven by BCR-ABL1 or SRC family kinases [80]. Here, SRC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.